Payers spoiled the debut of the first two PCSK9 drugs from Sanofi and Amgen. A third is poised for approval — but if history is any guide, its U.S. market-access path will be anything but smooth.
We analyze three winning rare disease campaigns that illustrate the challenges and opportunities that come with operating in such a difficult realm.
Tom Harrison cofounded Harrison & Star.
As part of the Medical Advertising Hall of Fame’s annual awards program, agencies nominate their brightest young stars as Future Famers.
Larry Lesser cofounded Medicus Communications and ApotheCom Associates.
John Kamp was executive director for the Coalition for Healthcare Communication.
The FDA granted Pfizer’s Ibrance a label indication based on real-world data from men using the drug off-label to treat their breast cancer.
While big tech’s promise to analyze America’s health data has tantalized and terrorized medical marketers, recent developments have pushed many players into a privacy panic.
The January 2020 issue includes a feature on the new face of the American doctor, an analysis of copay accelerators and a preview of CES Health 2020.
States have targeted co-pay accumulators, claiming they run up costs for patients who need expensive specialty drugs. Here’s why their legislation hasn’t yet had the intended impact.
Please login or register first to view this content.
